A Phase 2 interventional study of MYK-461 in Cardiomyopathy, Hypertrophic Obstructive and Left Ventricular Outflow Tract Obstruction, sponsored by MyoKardia, Inc.. Completed at 7 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-06-08.
Sponsored by MyoKardia, Inc. (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic — 3 open to participants now, 7 under way, 1 of them phase 3. MYK-461 · Cardiomyopathy, Hypertrophic.
Among the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, this one is the 19th largest by enrollment, is the only one that started in 2016, is one of 3 in phase 2, and was the 3rd registered.
363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.
Browse Cardiomyopathy, Hypertrophic studies →3 of the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic are open now, in 2 countries. Recruiting first, the newest first:
University of Manchester · Sites in United Kingdom
Ages 18+
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University
Ages 18+
By country, each count listing its studies:
MYK-461: first FDA approval 2022 (CAMZYOS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 7 · Phase 4 4
First in 2014; this study’s year is marked. 1 started in 2016.
This study's enrollment of 21 is below the median of 60 across 180 interventional studies indexed under Cardiomyopathy, Hypertrophic.
Median enrollment 75 across the 21 interventional studies. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 21 have an industry lead sponsor. The 7 most frequent:
This study is registered under MyoKardia, Inc., one of the names counted as Bristol-Myers Squibb. Under that name alone:
MyoKardia, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
31 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb: 9 open now, 14 under way, 1 of them phase 3. Of 17 finished, 8 (47%) have results posted.
Among the 31 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, this one is the 13th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2016, is one of 4 in phase 2, and was the 3rd registered.
Bristol-Myers Squibb’s Cardiomyopathy, Hypertrophic studies by the year they started, since 2014.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, from their registry updates:
Among Bristol-Myers Squibb’s 31 in Cardiomyopathy, Hypertrophic:
This tab as a report to print or save as PDF → With an account.
The purpose of this phase 2 open-label pilot study is to evaluate the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of MYK-461 in subjects with symptomatic HCM and LVOT obstruction aged 18-70 years.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MYK-461
Drug: MYK-461
Change in Post-exercise Peak LVOT Gradient From Baseline to Week 12
Post-exercise peak LVOT gradients are assessed after a treadmill stress test by echocardiography.
Time frame: Baseline and Week 12
Number of Participants Achieving a Post-exercise Peak LVOT Gradient Response of < 30 mmHg. Gradient < 30 mmHg
LVOT gradients are assessed after a treadmill stress test by echocardiography.
Time frame: Baseline and Week 12
Change in Dyspnea Symptom Score From Baseline to Week 12
The scale name is Dyspnea Numeric Rating Scale (NRS). It is intended to measure how much shortness of breath you have had in the past week. 0 = no shortness of breath and 10 = shortness of breath as the worst possible.
Time frame: Baseline and Week 12
Change in Peak VO2 From Baseline to Week 12
Peak VO2 is assessed using a cardiopulmonary exercise test.
Time frame: Baseline and Week 12
Change in VE/VCO2 From Baseline to Week 12
VE/VCO2 is assessed from cardiopulmonary exercise testing results.
Time frame: Baseline and Week 12
Change in Resting LVEF From Baseline to Week 12
LVEF is assessed by echocardiography.
Time frame: Baseline and Week 12
Change in LV Fractional Shortening (LVFS) From Baseline to Week 12
LVFS is assessed using echocardiography measures.
Time frame: Baseline and Week 12
Change in Global Longitudinal Strain (GLS) From Baseline to Week 12
GLS is assessed using echocardiography measures.
Time frame: Baseline and Week 12
Change in Post-exercise Peak LVOT Gradient From Week 12 to Week 16
Post-exercise peak LVOT gradients are assessed after a treadmill stress test by echocardiography.
Time frame: Weeks 12 and 16
Change in NYHA Functional Class From Baseline to Week 12
Time frame: Baseline and Week 12
Change in KCCQ OSS From Baseline to Week 12
Time frame: Baseline and Week 12
Change in NT-proBNP From Baseline to Week 12
Time frame: 12 weeks
Number of Subjects Achieving an LVOT Gradient Response of Post-exercise Peak Gradient < 10 mmHg at Week 12
Post-exercise peak LVOT gradients are assessed after a treadmill stress test by echocardiography.
Time frame: Baseline and Week 12
| Milestone | Cohort A | Cohort B |
|---|---|---|
| Started | 11 | 10 |
| Completed | 10 | 10 |
| Not completed | 1 | 0 |
Post-exercise peak LVOT gradients are assessed after a treadmill stress test by echocardiography.
| mm Hg | Cohort A | Cohort B |
|---|---|---|
| Change in Post-exercise Peak LVOT Gradient From Baseline to Week 12 | -89.5 (-138.3 to -40.7) | -25.0 (-47.1 to -3.0) |
LVOT gradients are assessed after a treadmill stress test by echocardiography.
| Participants | Cohort A | Cohort B |
|---|---|---|
| Number of Participants Achieving a Post-exercise Peak LVOT Gradient Response of < 30 mmHg. Gradient < 30 mmHg | 8 | 0 |
The scale name is Dyspnea Numeric Rating Scale (NRS). It is intended to measure how much shortness of breath you have had in the past week. 0 = no shortness of breath and 10 = shortness of breath as the worst possible.
| units on a scale | Cohort A | Cohort B |
|---|---|---|
| Change in Dyspnea Symptom Score From Baseline to Week 12 | -3.1 (-4.1 to -2.1) | -3.0 (-5.0 to -1.0) |
Peak VO2 is assessed using a cardiopulmonary exercise test.
| mL/kg/min | Cohort A | Cohort B |
|---|---|---|
| Change in Peak VO2 From Baseline to Week 12 | 3.5 (1.2 to 5.9) | 1.7 (0.03 to 3.3) |
VE/VCO2 is assessed from cardiopulmonary exercise testing results.
| Ratio | Cohort A | Cohort B |
|---|---|---|
| Change in VE/VCO2 From Baseline to Week 12 | -2.2 (-6.1 to 1.7) | -2.5 (-4.3 to -0.7) |
LVEF is assessed by echocardiography.
| Percent change | Cohort A | Cohort B |
|---|---|---|
| Change in Resting LVEF From Baseline to Week 12 | -14.6 (-23.1 to -6.2) | -5.5 (-9.8 to -1.2) |
LVFS is assessed using echocardiography measures.
| Percent | Cohort A | Cohort B |
|---|---|---|
| Change in LV Fractional Shortening (LVFS) From Baseline to Week 12 | -18.60 ± 13.05 | -3.98 ± 11.42 |
GLS is assessed using echocardiography measures.
| Percent | Cohort A | Cohort B |
|---|---|---|
| Change in Global Longitudinal Strain (GLS) From Baseline to Week 12 | 0.56 ± 3.778 | 0.18 ± 2.806 |
Post-exercise peak LVOT gradients are assessed after a treadmill stress test by echocardiography.
| mm Hg | Cohort A | Cohort B |
|---|---|---|
| Change in Post-exercise Peak LVOT Gradient From Week 12 to Week 16 | 55.22 ± 40.84 | 84.08 ± 28.38 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Post-exercise peak LVOT gradients are assessed after a treadmill stress test by echocardiography.
Results for this outcome have not been posted.
Collected over 16 Weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A | 0/11 (0%) | 1/11 (9.1%) | 10/11 (90.9%) |
| Cohort B | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Event | Cohort A | Cohort B |
|---|---|---|
| Atrial FibrillationCardiac disorders | 1/11 | 0/10 |
| Event | Cohort A | Cohort B |
|---|---|---|
| Ventricular TachycardiaCardiac disorders | 1/11 | 4/10 |
| DizzinessNervous system disorders | 1/11 | 3/10 |
| Atrial FibrillationCardiac disorders | 3/11 | 1/10 |
| HeadacheNervous system disorders | 3/11 | 2/10 |
| Ejection Fraction DecreasedInvestigations | 3/11 | 0/10 |
| Angina PectorisCardiac disorders | 0/11 | 2/10 |
| FatigueGeneral disorders | 2/11 | 2/10 |
| Application Site RashGeneral disorders | 0/11 | 2/10 |
| Upper Respiratory Tract InfectionInfections and infestations | 1/11 | 2/10 |
| NauseaGastrointestinal disorders | 2/11 | 0/10 |
| Age, Customized(years) | Cohort A | Cohort B | Total |
|---|---|---|---|
| Mean Age (range) | 56 (22 to 70) | 58 (26 to 67) | 57 (22 to 70) |
| Sex/Gender, Customized(Participants) | Cohort A | Cohort B | Total |
|---|---|---|---|
| Male | 7 | 5 | 12 |
| Female | 4 | 5 | 9 |
| Ethnicity (NIH/OMB)(Participants) | Cohort A | Cohort B | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 11 | 10 | 21 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort A | Cohort B | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 11 | 9 | 20 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Postexercise LVOT gradient(mm Hg) | Cohort A | Cohort B | Total |
|---|---|---|---|
| Mean | 103 ± 50 | 86 ± 43 | 94.5 ± 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2016 to primary completion in Nov 2017, 15 months.
Results were first posted in Feb 2020, 2 years 3 months after primary completion. A results delay was requested in Nov 2018.
Of 20 phase 2 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 43. This study's 15 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MYK-461
Cardiomyopathy, Hypertrophic →